Quarterly Results

BACIL PHARMA LTD.

NSE : NABSE : 524516ISIN CODE : INE711D01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE18.130.35 (+1.97 %)
PREV CLOSE ( ) 17.78
OPEN PRICE ( ) 18.13
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1513
TODAY'S LOW / HIGH ( )18.13 18.13
52 WK LOW / HIGH ( ) 4.6818.13
NSE
This Company is not listed in NSE
Quarters
Select year  
( in Million)
Particulars
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Audited / UnAudited
UnAudited
Audited
UnAudited
UnAudited
Net Sales
NA
NA
NA
NA
Total Expenditure
0.56
0.4
0.3
0.84
PBIDT (Excl OI)
-0.56
-0.4
-0.3
-0.84
Other Income
0.33
0.29
0.48
0.09
Operating Profit
-0.23
-0.11
0.18
-0.75
Interest
NA
NA
NA
NA
Exceptional Items
NA
NA
NA
NA
PBDT
-0.23
-0.11
0.18
-0.75
Depreciation
0.01
0.01
0.01
0.01
Profit Before Tax
-0.24
-0.12
0.17
-0.76
Tax
NA
NA
NA
NA
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
-0.24
-0.12
0.17
-0.76
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
0.00
0.00
0.00
0.00
Net Profit
-0.24
-0.12
0.17
-0.76
Equity Capital
58.9
58.9
58.9
58.9
Face Value (IN RS)
10
10
10
10
Reserves
Calculated EPS
-0.04
-0.02
0.02
-0.12
Calculated EPS (Annualised)
-0.16
-0.08
0.11
-0.51
No of Public Share Holdings
3376770
3376770
3376770
3376770
% of Public Share Holdings
57.33
57.33
57.33
57.33
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
NA
NA
NA
NA
PBIDTM%
NA
NA
NA
NA
PBDTM%
NA
NA
NA
NA
PBTM%
NA
NA
NA
NA
PATM%
NA
NA
NA
NA
 
Notes
Notes
Notes
Notes

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.